World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Dr Ulrike Lorch, MD FRCA FFPM
Medical Director

Dr Ulrike Lorch is the Medical Director of Richmond Pharmacology which she founded with Dr Jorg Taubel in 2001. Dr Lorch has conducted more than 220 early phase clinical studies in the capacity of Principal Investigator or co-investigator. She is accredited to conduct a range of Phase I studies, including those that - due to potential risks - require review by the Expert Advisory Group in addition to the standard review by the MHRA.

A specialist in adaptive study designs, her experience spans First-in-Human, ethnic comparison, cardiac safety (including TQT), pain, gastrointestinal pH monitoring studies and other exploratory studies in healthy volunteers and patients of all ages.

Dr Lorch was instrumental in obtaining Standard and Supplementary MHRA Phase I Accreditation – making Richmond Pharmacology one of the first clinical research units to gain this status.

Education

Dr Lorch studied medicine at the University of Frankfurt where she also received her postgraduate M.D. She then went on to achieve a Diploma in Pharmaceutical Medicine from the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and shortly after gained a fellowship with the Royal College of Anaesthetists.

Research

In addition to her studies at Richmond Pharmacology, Dr Lorch is a scientific lead at the Richmond Research Institute, a not-for-profit research organisation, where she leads the clinical trial design and methodology research group. She is currently investigating how computer-based automated learning could be used to develop an algorithm that provides grading for adverse drug reactions based on input factors such as symptoms, laboratory results and patient effects.

Awards and honours

Dr Lorch holds a Specialist Accreditation in Pharmaceutical Medicine and is a Fellow of the Royal College of Anaesthetists.

As a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, she supports trainee physicians in the capacity of Educational Supervisor for the Pharmaceutical Medicine Specialist Training, is a member of the Education Committee, the Board of Examiners, and a panel member for the Annual Review of Competence Progression.

Her memberships include the British Association of Pharmaceutical Physicians (BrAPP), the Trial Steering Group of the AGILE, the Japanese Society of Pharmacology and Therapeutics and the Arbeitsgemeinschaft fur Angewandte Humanpharmakologie (AGAH, Germany), a Committee member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI).

Ulrike is also a stakeholder representative for the UK and European regulatory bodies: MHRA and EMA as well as the Phase I Advisory Group (National Research Ethics Service, Health Research Authority).

Back to experts
r-gater-gater-gate

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more